$npx -y skills add Aperivue/medsci-skills --skill grant-builderGrant and challenge proposal support for radiology and medical AI projects. Structures significance, innovation, approach, milestones, and consortium roles while keeping claims evidence-based and executable.
| 1 | # Grant-Builder Skill |
| 2 | |
| 3 | ## Purpose |
| 4 | |
| 5 | This skill supports competitive proposal writing for: |
| 6 | |
| 7 | - national R&D grants |
| 8 | - multi-institution consortia |
| 9 | - challenge proposals |
| 10 | - internal pilot funding |
| 11 | - translational medical AI project plans |
| 12 | - **Korean government grants** (산학협력 / 연구계획서 — MOHW 복지부, MOTIE 산자부, MSS 중기부, and regional industry-academia programs) |
| 13 | |
| 14 | It is optimized for projects where clinical relevance, multi-site coordination, and executable milestones matter as much as technical novelty. |
| 15 | |
| 16 | --- |
| 17 | |
| 18 | ## Korean Government Grant Mode (산학과제 / 연구계획서) |
| 19 | |
| 20 | When the user requests a Korean industry-academia grant (산학과제) or research plan |
| 21 | (연구계획서), apply the adaptations below. Korean program terms are preserved in |
| 22 | parentheses because they are the literal form used on the funding agency's template. |
| 23 | |
| 24 | ### Document Structure (three-attachment format) |
| 25 | |
| 26 | Most Korean grants follow a standardized three-attachment format: |
| 27 | - **Attachment 1 (첨부1, 기본정보)**: project title, participating institutions, |
| 28 | investigator CVs, publication / patent record. |
| 29 | - **Attachment 2 (첨부2, 매칭확인서)**: per-institution cost-share confirmation, |
| 30 | typically finalized after a kickoff meeting between the institutions. |
| 31 | - **Attachment 3 (첨부3, 연구계획서)**: the 10-page research plan — structure below. |
| 32 | |
| 33 | ### Attachment 3 Standard Structure |
| 34 | |
| 35 | ``` |
| 36 | 1. Significance & Aims (약 2p) |
| 37 | - clinical problem with quantitative framing |
| 38 | - domestic + international trends (3–5 year literature / guideline window) |
| 39 | - differentiation of the proposed work |
| 40 | |
| 41 | 2. Research Content & Methods (약 4p) |
| 42 | - staged roadmap (Phase 1 – N with time ranges) |
| 43 | - pipeline schematic (mandatory when an AI pipeline is in scope) |
| 44 | - per-subproject institution and personnel assignment |
| 45 | |
| 46 | 3. Team Capability (약 1p) |
| 47 | - expertise + representative record (SCI papers, patents) per investigator |
| 48 | - cross-institution synergy (hospital = data / clinical; university = algorithm) |
| 49 | |
| 50 | 4. Expected Outcomes & Utilization (약 2p) |
| 51 | - quantitative targets: SCI papers, patents |
| 52 | - qualitative targets: clinical impact, standardization contribution |
| 53 | - linkage to follow-on larger grants (positioning as a seed) |
| 54 | |
| 55 | 5. Budget Plan (약 1p) |
| 56 | - RA salaries, computing equipment, consumables, academic activities, indirect costs |
| 57 | ``` |
| 58 | |
| 59 | ### Writing Tips for Small-Scale Grants (< KRW 30 million) |
| 60 | |
| 61 | - Write for a non-specialist reviewer — assume the evaluator is not in your subfield. |
| 62 | - Emphasize feasibility over technical novelty. |
| 63 | - Prioritize length / format compliance; exceeding the template incurs scoring penalties. |
| 64 | - Include preliminary data or pilot results whenever available. |
| 65 | - Keep quantitative targets conservative — undershooting a committed target is punished |
| 66 | more than overdelivering on a modest one. |
| 67 | |
| 68 | --- |
| 69 | |
| 70 | ## Communication Rules |
| 71 | |
| 72 | - Communicate with the user in their preferred language. |
| 73 | - Proposal prose should be in the language required by the target call. |
| 74 | - Avoid hype. Emphasize unmet need, feasibility, differentiation, and deliverables. |
| 75 | |
| 76 | --- |
| 77 | |
| 78 | ## Core Outputs |
| 79 | |
| 80 | Depending on the request, produce one or more of: |
| 81 | |
| 82 | - project concept summary |
| 83 | - `Significance` |
| 84 | - `Innovation` |
| 85 | - `Approach` |
| 86 | - specific aims |
| 87 | - work packages |
| 88 | - milestone table |
| 89 | - role split by institution |
| 90 | - evaluation framework |
| 91 | - reviewer-risk memo |
| 92 | |
| 93 | --- |
| 94 | |
| 95 | ## Workflow |
| 96 | |
| 97 | ### Phase 1: Decode the funding call |
| 98 | |
| 99 | Extract: |
| 100 | - funding body |
| 101 | - call theme |
| 102 | - eligibility constraints |
| 103 | - deliverable expectations |
| 104 | - timeline |
| 105 | - evaluation criteria |
| 106 | |
| 107 | If no call text is available, infer a generic academic-medical AI proposal structure and label assumptions. |
| 108 | |
| 109 | ### Phase 2: Frame the problem |
| 110 | |
| 111 | Define: |
| 112 | - clinical pain point |
| 113 | - current workflow limitation |
| 114 | - why existing AI or standard care is insufficient |
| 115 | - who benefits if the project succeeds |
| 116 | |
| 117 | **Gate:** Present the problem framing (clinical pain point, gap, proposed solution) to the |
| 118 | user. Confirm before building proposal sections — a misframed problem produces an |
| 119 | unfundable proposal. |
| 120 | |
| 121 | ### Phase 3: Build the proposal spine |
| 122 | |
| 123 | Always articulate: |
| 124 | - problem |
| 125 | - gap |
| 126 | - proposed solution |
| 127 | - why this team can execute it |
| 128 | - measurable outputs |
| 129 | |
| 130 | ### Phase 4: Convert to proposal sections |
| 131 | |
| 132 | #### Significance |
| 133 | |
| 134 | Must answer: |
| 135 | - why this matters clinically |
| 136 | - why this matters now |
| 137 | - why the proposed solution is worth funding |
| 138 | |
| 139 | #### Innovation |
| 140 | |
| 141 | Should focus on: |
| 142 | - what is genuinely different |
| 143 | - why the integration is new |
| 144 | - why the novelty is useful, not just technical |
| 145 | |
| 146 | #### Approach |
| 147 | |
| 148 | Should define: |
| 149 | - dataset and participating sites |
| 150 | - model or workflow components |
| 151 | - validation plan |
| 152 | - benchmark/comparator |
| 153 | - failure analysis |
| 154 | - risk mitigation |
| 155 | |
| 156 | ### Phase 5: E |